SCHEMBL3586733

SCHEMBL3586733

CCCCc1c(C(=O)N(C)Cc2ccc3ncccc3c2)[nH]c(C(N)=O)c1S(=O)(=O)c1cccc(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 1/20 0.37
BRD4 O60885 1/20 0.36
BRD3 Q15059 1/20 0.36
PDK1 Q15118 2/20 0.35
MAPK1 P28482 2/20 0.35
ALDH1A1 P00352 2/20 0.35
RAB9A P51151 2/20 0.35
APLNR P35414 3/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
USP30 Q70CQ3 1/20 0.34
FFAR2 O15552 1/20 0.34
TNF P01375 1/20 0.33
NOD2 Q9HC29 1/20 0.33
NOD1 Q9Y239 1/20 0.33
PIN1 Q13526 1/20 0.33
GRM5 P41594 1/20 0.33
HTR6 P50406 1/20 0.33
RECQL P46063 1/20 0.33
MCL1 Q07820 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3590262 0.94 SPR (0.38) SPRBRD4BRD3PDK1MAPK1
SCHEMBL3574643 0.93 SPR (0.38) SPRBRD4BRD3PDK1MAPK1
SCHEMBL3581443 0.92 PDK1 (0.41) SPRBRD4BRD3PDK1MAPK1
SCHEMBL3590189 0.90 SPR (0.38) SPRBRD4BRD3PDK1MAPK1
SCHEMBL3586109 0.87 PDK1 (0.42) SPRBRD4BRD3PDK1MAPK1
SCHEMBL3579566 0.84 PDK1 (0.43) SPRBRD4BRD3PDK1MAPK1
SCHEMBL3590929 0.83 SPR (0.40) SPRBRD4BRD3PDK1MAPK1
SCHEMBL3584400 0.80 SPR (0.38) SPRBRD4BRD3PDK1MAPK1
SCHEMBL3593677 0.79 NAMPT (0.38) SPRPDK1MAPK1ALDH1A1RAB9A
SCHEMBL3583754 0.78 SPR (0.41) SPRBRD4BRD3PDK1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US claimed
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS RTF1, RNGTT, POLR2E SPR 217/4885BRD4 2472/4885BRD3 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.